Small Cap Active Stocks: FuelCell Energy (NASDAQ:FCEL), Ariad Pharmaceuticals (NASDAQ:ARIA), KB Home (NYSE:KBH), Endocyte (NASDAQ:ECYT)

Shares of Plug Power Inc. (NASDAQ:FCEL) fell 9% on Friday, and the stock was moving toward ending the week down nearly 20% as investors’ enthusiasm for it seemed to have dried up — at least for now. FuelCell Energy Inc (NASDAQ:FCEL) stock performance was 6.64% in last session and finished the day at $2.57. Traded volume was 29.87million shares in the last session and the average volume of the stock remained 20.77million shares. The beta of the stock remained 2.35. FuelCell Energy Inc (NASDAQ:FCEL) insider ownership is 0.80%.

Ariad Pharmaceuticals (NASDAQ:ARIA) Insider Timothy P. Clackson unloaded 6,667 shares of the stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $7.89, for a total transaction of $52,602.63. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) dropped -3.57 percent to $7.84 Friday on volume of 13.35million shares. The intra-day range of the stock was $7.76 to $8.23. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a market capitalization of $1.46billion.

KB Home (NYSE:KBH) has received an average recommendation of “Hold” from the twenty-seven analysts that are currently covering the company, American Banking News reports. KB Home (NYSE:KBH)’s stock on Mar 21, 2014 reported a decrease of -2.31% to the closing price of $17.79. Its fifty two weeks range is $15.48-$25.14. The total market capitalization recorded $1.68billion. The overall volume in the last trading session was 14.66million shares. In its share capital, KBH has 83.74million outstanding shares.

Endocyte, Inc. (NASDAQ:ECYT) stock skyrocketed over 130% today (Friday) after the Indiana-based biopharma won market approval for its first drug, a cancer therapeutic called “vintafolide.” The drug was developed in collaboration with Merck & Co. On Friday, shares of Endocyte, Inc. (NASDAQ:ECYT) advanced 92.42% to close the day at $28.17. Company return on investment (ROI) is -20.70% and its monthly performance is recorded as 89.44%. Endocyte, Inc. (NASDAQ:ECYT) quarterly revenue growth is 179.74%.